Development and pre-clinical assessment of a 73kD chimeric fusion protein as a defined sub-unit vaccine for leprosy

Vaccine

Volumn 31, Issue 5, 2013, Pages 813-819

  Duthie, Malcolm S ^a   Sampaio, Lucas H ^b   Oliveira, Regiane M ^b   Raman, Vanitha S ^a   O'Donnell, Joanne ^a   Bailor, H Remy ^a   Ireton, Greg C ^a   Sousa, Ana Lucia M ^b   Stefani, Mariane M A ^b   Reed, Steven G ^a  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^b FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

Author keywords

Leprosy; Mycobacteria; T cell; Vaccine

Indexed keywords

73F CHIMERIC FUSION PROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN G; LEPROSY VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; IMMUNIZATION; LEPROSY; MALE; MOUSE; MYCOBACTERIUM LEPRAE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL VACCINES; FEMALE; HUMANS; IMMUNOGLOBULIN G; INTERFERON-GAMMA; LEPROSY; LEUKOCYTES, MONONUCLEAR; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; MYCOBACTERIUM LEPRAE; RECOMBINANT FUSION PROTEINS; TH1 CELLS; VACCINES, SYNTHETIC; YOUNG ADULT;

EID: 84872605957     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.11.073     Document Type: Article

References (28)

1. WHO. Global leprosy situation, 2009. Wkly Epidemiol Rec 2009, 84(33):333-340.
2. Meima A., Richardus J.H., Habbema J.D. Trends in leprosy case detection worldwide since 1985. Lepr Rev 2004, 75(1):19-33.
3. Meima A., Smith W.C., van Oortmarssen G.J., Richardus J.H., Habbema J.D. The future incidence of leprosy: a scenario analysis. Bull World Health Organ 2004, 82(5):373-380.
4. Setia M.S., Steinmaus C., Ho C.S., Rutherford G.W. The role of BCG in prevention of leprosy: a meta-analysis. Lancet Infect Dis 2006, 6(3):162-170.
5. Duthie M.S., Gillis T.P., Reed S.G. Advances and hurdles on the way toward a leprosy vaccine. Human Vaccines 2011, 7(11):1172-1183.
6. Duthie M.S., Reece S.T., Lahiri R., Goto W., Raman V.S., Kaplan J., Ireton G.C., Bertholet S., Gillis T.P., Krahenbuhl J.L., et al. Antigen-specific cellular and humoral responses are induced by intradermal Mycobacterium leprae infection of the mouse ear. Infect Immun 2007, 75(11):5290-5297.
7. Duthie M.S., Goto W., Ireton G.C., Reece S.T., Sampaio L.H., Grassi A.B., Sousa A.L., Martelli C.M., Stefani M.M., Reed S.G. Antigen-specific T-cell responses of leprosy patients. Clin Vaccine Immunol 2008, 15(11):1659-1665.
8. Duthie M.S., Goto W., Ireton G.C., Reece S.T., Cardoso L.P., Martelli C.M., Stefani M.M., Nakatani M., de Jesus R.C., Netto E.M., et al. Use of protein antigens for early serological diagnosis of leprosy. Clin Vaccine Immunol 2007, 14(11):1400-1408.
9. Baldwin S.L., Shaverdian N., Goto Y., Duthie M.S., Raman V.S., Evers T., Mompoint F., Vedvick T.S., Bertholet S., Coler R.N., et al. Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 2009, 27(43):5956-5963.
10. Coler R.N., Baldwin S.L., Shaverdian N., Bertholet S., Reed S.J., Raman V.S., Lu X., DeVos J., Hancock K., Katz J.M., et al. A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS One 2010, 5(10):e13677.
11. Shepard C.C., McRae D.H. A method for counting acid-fast bacteria. Int J Lepr Other Mycobact Dis 1968, 36(1):78-82.
12. Lahiri R., Randhawa B., Krahenbuhl J. Application of a viability-staining method for Mycobacterium leprae derived from the athymic (nu/nu) mouse foot pad. J Med Microbiol 2005, 54(Pt 3):235-242.
13. Sampaio L.H., Sousa A.L., Barcelos M.C., Reed S.G., Stefani M.M., Duthie M.S. Evaluation of various cytokines elicited during antigen-specific recall as potential risk indicators for the differential development of leprosy. Eur J Clin microbiol Infect Dis 2011.
14. Sampaio L.H., Stefani M.M., Oliveira R.M., Sousa A.L., Ireton G.C., Reed S.G., Duthie M.S. Immunologically reactive M. leprae antigens with relevance to diagnosis and vaccine development. BMC Infect Dis 2011, 11:26.
15. Spencer J.S., Kim H.J., Wheat W.H., Chatterjee D., Balagon M.V., Cellona R.V., Tan E.V., Gelber R., Saunderson P., Duthie M.S., et al. Analysis of antibody responses to Mycobacterium leprae phenolic glycolipid I, lipoarabinomannan, and recombinant proteins to define disease subtype-specific antigenic profiles in leprosy. Clin Vaccine Immunol: CVI 2011, 18(2):260-267.
16. Geluk A., Spencer J.S., Bobosha K., Pessolani M.C., Pereira G.M., Banu S., Honore N., Reece S.T., MacDonald M., Sapkota B.R., et al. From genome-based in silico predictions to ex vivo verification of leprosy diagnosis. Clin Vaccine Immunol 2009, 16(3):352-359.
17. Lahiri R., Randhawa B., Franken K.L.M.C., Duthie M.S., Spencer J.S., Geluk A., Krahenbuhl J.S.L. Development of a mouse food pad model for detection of sub clinical leprosy. Lepr Rev 2011, 82.
18. Adams L.B., Scollard D.M., Ray N.A., Cooper A.M., Frank A.A., Orme I.M., Krahenbuhl J.L. The study of Mycobacterium leprae infection in interferon-gamma gene - Disrupted mice as a model to explore the immunopathologic spectrum of leprosy. J Infect Dis 2002, 185(Suppl 1):S1-S8.
19. Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W., Davey D.F., Flynn B.J., Hoff S.T., Andersen P., Reed S.G., Morris S.L., et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007, 13(7):843-850.
20. Harari A., Dutoit V., Cellerai C., Bart P.A., Du Pasquier R.A., Pantaleo G. Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol Rev 2006, 211:236-254.
21. Nambiar J.K., Pinto R., Aguilo J.I., Takatsu K., Martin C., Britton W.J., Triccas J.A. Protective immunity afforded by attenuated, PhoP-deficient Mycobacterium tuberculosis is associated with sustained generation of CD4+ T-cell memory. Eur J Immunol 2012, 42(2):385-392.
22. Narang T., Kaur I., Kumar B., Radotra B.D., Dogra S. Comparative evaluation of immunotherapeutic efficacy of BCG and mw vaccines in patients of borderline lepromatous and lepromatous leprosy. Int J Lepr Other Mycobact Dis 2005, 73(2):105-114.
23. Wakhlu A., Gaur S.P., Kaushal G.P., Misra A., Asthana P., Sircar A.R. Response of Mycobacterium habana vaccine in patients with lepromatous leprosy and their household contacts. A pilot clinical study. Lepr Rev 2001, 72(2):179-191.
24. Shepard C.C. The experimental disease that follows the injection of human leprosy bacilli into foot-pads of mice. J Exp Med 1960, 112:445-454.
25. Job C.K., Sanchez R.M., Hunt R., Truman R.W., Hastings R.C. Armadillos (Dasypus novemcinctus) as a model to test antileprosy vaccines; a preliminary report. Int J Lepr Other Mycobact Dis 1993, 61(3):394-397.
26. Scollard D.S., Truman R.W. Armadillos as animal models for lepromatous neuropathy. Animal Models for Biomedical Research 1999, 330-336. Academic Press, New York. Deason (Ed.).
27. Truman R.W., Sanchez R.M. Armadillos models for leprosy. Lab Animal 1993, 22:28-32.
28. Raman V.S., O'Donnell J., Bailor H.R., Goto W., Lahiri R., Gillis T.P., Reed S.G., Duthie M.S. Vaccination with the ML0276 antigen reduces local inflammation but not bacterial burden during experimental Mycobacterium leprae infection. Infect Immun 2009, 77(12):5623-5630.